A phase 1, multicenter study evaluated the use of PvD in patients with proteasome inhibitor–exposed and lenalidomide-refractory multiple myeloma to examine the maximum tolerated dose with secondary end points of safety, overall response rate, duration of response, and time to response.

The phase 1/2 Alliance study sought to evaluate the safety and preliminary efficacy of the combination of ixazomib/pomalidomide/dexamethasone in patients with double-refractory multiple myeloma compared with the approved combination of pomalidomide/dexamethasone. Here, they report the phase 1 portion of the Alliance study.

Investigators examined the safety and efficacy of the combination of lenalidomide/ixazomib as a maintenance therapy after ASCT in a single-arm phase 2 study. Favorable results of this combination may warrant additional examination in a phase 3 study.

Results of a randomized, phase 2 study to determine the confirmed overall response rate in patients treated with ixazomib, an orally bioavailable proteasome inhibitor, for patients with relapsed multiple myeloma not refractory to bortezomib.

The ENDEAVOR study demonstrated that carfilzomib plus dexamethasone showed a significant improvement in median progression-free survival compared with bortezomib plus dexamethasone. This update examines outcomes in patients in high-risk cytogenetic subgroups.

Using a combined analysis of 2 DARA clinical studies, researchers assessed the overall response rates and clinical activity of a 16-mg/kg infusion for the treatment of relapsed and refractory multiple myeloma in heavily treated patients.

In a phase 3 study, researchers assessed the safety and efficacy of elotuzumab plus lenalidomide/dexamethasone, the first immunostimulatory monoclonal antibody for the treatment of relapsed/refractory multiple myeloma. Here, they report 3-year follow-up data.

Researchers report the significant and lasting improvement in progression-free survival and overall survival in patients treated with bortezomib. A subgroup analysis identified bortezomib to have an effect on the high-risk effects of del(17p) and renal impairment on survival.

Researchers report the results of a phase 2 study evaluating the tolerability and long-term outcomes using a combination of ixazomib plus cyclophosphamide and low-dose dexamethasone in newly diagnosed multiple myeloma (MM) patients who are not eligible for transplant.